Drug-Eluting Balloons

This channel includes news and new technology innovations for drug coated balloons, also referred to as drug-eluting balloons. These are used to treat peripheral and coronary artery lesions and restenosis.

News | December 28, 2011

December 28, 2011 – Good Samaritan Hospital in Los Angeles is participating in the Levant 2 clinical trial to...

News | November 14, 2011

November 14, 2011 — A clinical trial of patients with restenosis in drug-eluting stents (DES) in native coronary...

News | November 14, 2011

November 14, 2011 – Medrad Inc. announced that five-year data from the THUNDER trial [1] demonstrated a 59 percent...

News | September 16, 2011

September 15, 2011 – The Cardiovascular Research Foundation (CRF) has announced the late breaking trials and first...

News | September 15, 2011

September 15, 2011 — Very positive results were reported in the first account of a clinical study evaluating the...

News | July 26, 2011

July 26, 2011 – The first patient has been enrolled in the LEVANT 2 clinical trial, a global, multi-center,...

News | May 18, 2011

May 17, 2011 - Medrad Inc., a business of Bayer HealthCare, today announced it has received CE Mark for its...

News | November 17, 2010

November 17, 2010 – A drug-eluting balloon (DEB) and a coronary stent have received CE mark approval in Europe. The...

News | September 29, 2010

September 29, 2010 – Results from a trial studying the effects of a drug-eluting balloon (DEB) on...

News | May 25, 2010

May 25, 2010 – The first patient has been implanted with a bare metal coronary stent mounted on a drug-...

The Paccocath coating of the B.Braun SeQuent Please DEB uses contrast media to separate and evenly distribute the paclitaxel molecules over the surface of the balloon. The anti-proliferative drug helps prevent restenosis.

Feature | May 03, 2010 | Dave Fornell

Several paclitaxel drug-eluting balloons (DEBs) are currently available on the European market, and several others...

An illustration showing how the Amphirion_drug-eluting, drug-coated balloon technology works.

Invatec developed the FreePac balloon coating, which uses a urea matrix to free and separate paclitaxel molecules and facilitates their absorption into the blood vessel wall.

Feature | Drug-Eluting Balloons | May 03, 2010 | Dave Fornell

Drug-eluting balloons (DEBs) may offer new options in treating peripheral vessels and restenosis. DEBs...

A radio frequency plaque ablation system is combined inside the Minnow Guiding Reshaping Technology balloon catheter.

Feature | May 02, 2010 | By Stephanie Labelle, senior analyst, Millennium Research Group

In recent years, many medical device companies saw the underserved lower extremity as an opportunity to...

The SeQuent Please drug-eluting balloon catheter was cleared for use in Europe in 2009.

News | February 22, 2010

February 22, 2010 – As part of a comarketing and trademark license agreement between MEDRAD Inc. and B....

Medtronic's purchased of Invatec will expand its portfolio of devices to treat peripheral artery disease (PAD).

News | January 25, 2010

January 25, 2010 – Expanding its peripheral vascular disease product offerings, Medtronic Inc. today signed...

Overlay Init